Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2013 | Original Article

High ¹²³I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology

Authors: Wolfgang Peter Fendler, Henriette Ingrid Melzer, Christoph Walz, Dietrich von Schweinitz, Eva Coppenrath, Irene Schmid, Peter Bartenstein, Thomas Pfluger

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2013

Abstract

Purpose

Scintigraphy using ¹²³I-metaiodobenzylguanidine (¹²³I-MIBG) is widely used for the detection of neuroblastic tumours. The aim of this study was to identify a possible correlation between the uptake intensity on ¹²³I-MIBG SPECT and histopathology of neuroblastic tumours.

Methods

¹²³I-MIBG SPECT examinations were performed in 55 paediatric patients with neuroblastic tumour and compared to histopathology after surgical resection or biopsy at a mean of 2 weeks after SPECT. For each lesion International Neuroblastoma Pathology Classification System (INPC) stage, mitosis karyorrhexis index (MKI), location and a semiquantitative tumour-to-liver count-rate ratio (TLCRR) were determined. Also, the presence or absence of MYCN amplification, p1 deletion, urine catecholamine and neuron-specific enolase blood levels at the time of scanning were recorded.

Results

In the 55 patients, 61 lesions were evaluated with ¹²³I-MIBG SPECT and corresponding histopathological findings were reviewed (11 ganglioneuroma, 11 ganglioneuroblastoma and 39 neuroblastoma). TLCRR was significantly higher in the neuroblastoma group (mean TLCRR 2.7) than in the ganglioneuroblastoma group (mean TLCRR 1.0) and ganglioneuroma group (mean TLCRR 0.7) at the time of primary diagnosis (p < 0.001) and at follow-up (p = 0.039). Intense ¹²³I-MIBG uptake was found in tumour tissue with a high mitotic activity (MKI-high or MKI-intermediate) after treatment. Four ganglioneuromas (36 %), three ganglioneuroblastomas (27 %) and six neuroblastomas (15 %) were ¹²³I-MIBG-negative.

Conclusion

In paediatric patients with peripheral neuroblastic tumours, strong ¹²³I-MIBG uptake indicates unfavourable histopathology. High uptake was seen in neuroblastomas and in tumours with a high mitotic activity.

Grosfeld JL, Skinner MA, Rescorla FJ, West KW, Scherer III LR. Mediastinal tumors in children: experience with 196 cases. Ann Surg Oncol. 1994;1:121–7.PubMedCrossRef

Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999;86:349–63.PubMedCrossRef

Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999;86:364–72.PubMedCrossRef

Klijanienko J, Couturier J, Brisse H, Pierron G, Freneaux P, Berger F, et al. Diagnostic and prognostic information obtained on fine-needle aspirates of primary neuroblastic tumors: proposal for a cytology prognostic score. Cancer Cytopathol. 2011;119:411–23.PubMedCrossRef

Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.PubMed

Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005;17:7–13.PubMedCrossRef

Castleberry RP, Pritchard J, Ambros P, Berthold F, Brodeur GM, Castel V, et al. The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer. 1997;33:2113–6.PubMedCrossRef

Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children’s Cancer Group study. J Clin Oncol. 1998;16:1256–64.PubMed

Freitas JE. Adrenal cortical and medullary imaging. Semin Nucl Med. 1995;25:235–30.PubMedCrossRef

10.

Mairs RJ, Livingstone A, Gaze MN, Wheldon TE, Barrett A.Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction. Br J Cancer. 1994;70:97–101.PubMedCrossRef

11.

Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JC, et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. 2009;52:784–90.PubMedCrossRef

12.

Sharp SE, Gelfand MJ, Shulkin BL. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med. 2011;41:345–53.PubMedCrossRef

13.

Spitz R, Hero B, Ernestus K, Berthold F. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res. 2003;9:52–8.PubMed

14.

Olivier P, Colarinha P, Fettich J, Fischer S, Frokier J, Giammarile F, et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging. 2003;30:B45–50.PubMedCrossRef

15.

Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998;39:679–88.PubMed

16.

Feine U, Muller-Schauenburg W, Treuner J, Klingebiel T. Metaiodobenzylguanidine (MIBG) labeled with 123I/131I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Pediatric Oncology held in Rome, September 1986. Med Pediatr Oncol. 1987;15:181–7.PubMedCrossRef

17.

Heyman S, Evans AE. lodine-131-metaiodobenzylguanidine (I-131-MIBG) in the diagnosis of neuroblastoma. J Nucl Med. 1986;27:931.

18.

Okuyama C, Ushijima Y, Watanabe K, Sugihara H, Nishimura T. Iodine-123-MIBG scintigraphy in neuroblastoma; relationship between the intensity of uptake and tumor characteristics. Kaku Igaku. 1999;36:827–34.PubMed

19.

Biasotti S, Garaventa A, Villavecchia GP, Cabria M, Nantron M, De Bernardi B. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol. 2000;35:153–5.PubMedCrossRef

20.

Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996;199:743–50.PubMed

21.

Melzer HI, Coppenrath E, Schmid I, Albert MH, von Schweinitz D, Tudball C, et al. 123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging. 2011;38:1648–58.PubMedCrossRef

22.

Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50:1237–43.PubMedCrossRef

23.

Lu MY, Liu YL, Chang HH, Jou ST, Yang YL, Lin KH, et al. Characterization of neuroblastic tumors using 18F-FDOPA PET. J Nucl Med. 2013;54:42–9.PubMedCrossRef

24.

Taggart DR, London WB, Schmidt ML, DuBois SG, Monclair TF, Nakagawara A, et al. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011;29:4358–64.PubMedCrossRef

25.

George RE, Perez-Atayde AR, Yao X, London WB, Shamberger RC, Neuberg D, et al. Tumor histology during induction therapy in patients with high-risk neuroblastoma. Pediatr Blood Cancer. 2012;59:506–10.PubMedCrossRef

26.

Wenzel A, Cziepluch C, Hamann U, Schurmann J, Schwab M. The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells. EMBO J. 1991;10:3703–12.PubMed

27.

Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. Cancer. 2001;92:2699–708.PubMedCrossRef

28.

White PS, Maris JM, Beltinger C, Sulman E, Marshall HN, Fujimori M, et al. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2–36.3. Proc Natl Acad Sci U S A. 1995;92:5520–4.PubMedCrossRef

29.

Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353:2243–53.PubMedCrossRef

Title: High 123I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology
Authors: Wolfgang Peter Fendler
Henriette Ingrid Melzer
Christoph Walz
Dietrich von Schweinitz
Eva Coppenrath
Irene Schmid
Peter Bartenstein
Thomas Pfluger
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2491-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

High ¹²³I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2013

Real-time FDG PET/CT-guided bone biopsy in a patient with two primary malignancies

Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis

Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies

Evaluation of cannabinoid type 1 receptor expression in the rat brain using [18F]MK-9470 microPET

A prospective analysis of 18F-FDG PET/CT in patients with uveal melanoma: comparison between metabolic rate of glucose (MRglu) and standardized uptake value (SUV) and correlations with histopathological features

Freehand SPECT for image-guided sentinel lymph node biopsy in breast cancer